These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 17133107)

  • 1. Medullary thyroid cancer: therapeutic targets and molecular markers.
    Ball DW
    Curr Opin Oncol; 2007 Jan; 19(1):18-23. PubMed ID: 17133107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beyond RET: potential therapeutic approaches for advanced and metastatic medullary thyroid carcinoma.
    Santarpia L; Ye L; Gagel RF
    J Intern Med; 2009 Jul; 266(1):99-113. PubMed ID: 19522829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of medullary thyroid cancer.
    Ball DW
    Minerva Endocrinol; 2011 Mar; 36(1):87-98. PubMed ID: 21460789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Medullary thyroid carcinoma and biomarkers: past, present and future.
    van Veelen W; de Groot JW; Acton DS; Hofstra RM; Höppener JW; Links TP; Lips CJ
    J Intern Med; 2009 Jul; 266(1):126-40. PubMed ID: 19522831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New therapeutic approaches to treat medullary thyroid carcinoma.
    Schlumberger M; Carlomagno F; Baudin E; Bidart JM; Santoro M
    Nat Clin Pract Endocrinol Metab; 2008 Jan; 4(1):22-32. PubMed ID: 18084343
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular genetics of medullary thyroid carcinoma: the quest for novel therapeutic targets.
    Cerrato A; De Falco V; Santoro M
    J Mol Endocrinol; 2009 Oct; 43(4):143-55. PubMed ID: 19383830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medullary thyroid carcinoma.
    Leboulleux S; Baudin E; Travagli JP; Schlumberger M
    Clin Endocrinol (Oxf); 2004 Sep; 61(3):299-310. PubMed ID: 15355445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New molecular targeted therapies in thyroid cancer.
    Milano A; Chiofalo MG; Basile M; Salzano de Luna A; Pezzullo L; Caponigro F
    Anticancer Drugs; 2006 Sep; 17(8):869-79. PubMed ID: 16940797
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The RET kinase inhibitor NVP-AST487 blocks growth and calcitonin gene expression through distinct mechanisms in medullary thyroid cancer cells.
    Akeno-Stuart N; Croyle M; Knauf JA; Malaguarnera R; Vitagliano D; Santoro M; Stephan C; Grosios K; Wartmann M; Cozens R; Caravatti G; Fabbro D; Lane HA; Fagin JA
    Cancer Res; 2007 Jul; 67(14):6956-64. PubMed ID: 17638907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of medullary thyroid carcinoma.
    Jiménez C; Hu MI; Gagel RF
    Endocrinol Metab Clin North Am; 2008 Jun; 37(2):481-96, x-xi. PubMed ID: 18502338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medullary thyroid cancer: molecular biology and novel molecular therapies.
    Cakir M; Grossman AB
    Neuroendocrinology; 2009; 90(4):323-48. PubMed ID: 19468197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis.
    Rodríguez-Antona C; Pallares J; Montero-Conde C; Inglada-Pérez L; Castelblanco E; Landa I; Leskelä S; Leandro-García LJ; López-Jiménez E; Letón R; Cascón A; Lerma E; Martin MC; Carralero MC; Mauricio D; Cigudosa JC; Matias-Guiu X; Robledo M
    Endocr Relat Cancer; 2010 Mar; 17(1):7-16. PubMed ID: 19776290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer.
    Schlumberger MJ; Elisei R; Bastholt L; Wirth LJ; Martins RG; Locati LD; Jarzab B; Pacini F; Daumerie C; Droz JP; Eschenberg MJ; Sun YN; Juan T; Stepan DE; Sherman SI
    J Clin Oncol; 2009 Aug; 27(23):3794-801. PubMed ID: 19564535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel chemotherapy options for advanced thyroid tumors: small molecules offer great hope.
    Deshpande HA; Gettinger SN; Sosa JA
    Curr Opin Oncol; 2008 Jan; 20(1):19-24. PubMed ID: 18043252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.
    van Veelen W; van Gasteren CJ; Acton DS; Franklin DS; Berger R; Lips CJ; Höppener JW
    Cancer Res; 2008 Mar; 68(5):1329-37. PubMed ID: 18316595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Medullary thyroid cancer: a promising model for targeted therapy.
    Torino F; Paragliola RM; Barnabei A; Corsello SM
    Curr Mol Med; 2010 Oct; 10(7):608-25. PubMed ID: 20712590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapeutic advances in the management of progressive thyroid cancer.
    Woyach JA; Shah MH
    Endocr Relat Cancer; 2009 Sep; 16(3):715-31. PubMed ID: 19218279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medullary thyroid cancer: early detection and novel treatments.
    Roman S; Mehta P; Sosa JA
    Curr Opin Oncol; 2009 Jan; 21(1):5-10. PubMed ID: 19125012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma.
    Messina M; Robinson BG
    Nat Clin Pract Endocrinol Metab; 2007 Mar; 3(3):290-301. PubMed ID: 17315037
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Medullary thyroid carcinoma: surgical treatment advances.
    Dionigi G; Bianchi V; Rovera F; Boni L; Piantanida E; Tanda ML; Dionigi R; Bartalena L
    Expert Rev Anticancer Ther; 2007 Jun; 7(6):877-85. PubMed ID: 17555398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.